Drug Interactions Involving the Cytochrome P450 Enzymes: Analysis of Common Combinations of Antibiotics and Pain Relieving Drugs

Saskia Preissner1*, Daniel Kuzman1 and Nicole Pischon2
1Department of Operative and Preventive Dentistry, Charité – Universitätsmedizin Berlin, Germany
2Department of Periodontology, Charité – Universitätsmedizin Berlin, Germany

Abstract

Objective: For clinicians it is challenging to oversee complex drug interactions of multi-drug administration. Rheumatoid arthritis (RA) patients are frequently under long-term medication with multiple anti-inflammatory and pain-relieving drugs, which are mainly metabolized by the Cytochrome P450 enzymes (CYPs). Additionally, treatment of co-medications, such as inflammatory periodontal disease (PD) may have to involve further drug administration. The aim of this investigation was to analyze drug interactions in the therapy of RA and PD and to provide a resource for health professionals to easily check interactions and avoid potential side effects.

Methods: Information on drug administration in the therapy of RA and PD and expression data of human tissues regarding CYPs was gathered and/or analyzed from scientific literature and web resources. A literature compilation was developed and CYP interaction tables were generated.

Results: Side effects, such as enzyme overload or enzyme induction and inhibition may occur in the therapy of RA and PD. To overcome these problems, a web-interface was developed to optimize drug cocktails. The compilation provides manually curated information on the metabolism of 1,500 drugs including 100,000 PubMed references, covering a variety of co-morbidities. Moreover, based on the WHO classification system for drugs (ATC-codes), the knowledge base offers drug alternatives, avoiding CYP-related problems. The web-interface is publicly available: http://bioinformatics.charite.de/peri

Conclusions: After a detailed drug anamnesis, health professionals should use a web-interface to check drug interactions involving CYP metabolism, which may circumvent adverse side effects and optimize interdisciplinary drug therapy.

Introduction

Rheumatoid arthritis (RA) is the most frequent inflammatory joint disease affecting more than 50 million people worldwide [1]. RA patients are frequently treated with pain relieving and anti-inflammatory drugs (NSAIDs). Furthermore, corticosteroids, disease-modifying anti-rheumatic drugs (DMARDs) and biologics are administered depending on RA severity and progression [2]. In 2008, a world-wide group of rheumatologists developed a set of recommendations for the RA treatment, which is updated at regular intervals [3]. The recommendations are target-based on evidence and expert opinion. The primary treatment aim is the clinical disease remission. Also, the individual drug therapy is at least adjusted every three months, which requires frequent drug anamnesis and adaptation by health professionals besides rheumatologists.

The RA etiology is unclear, however next to genetic and environmental factors such as age, gender, HLA genotype and smoking, bacterial infections seem to play an important role [4]. It is proposed that RA results from a failure of the immune response attacking an unknown antigen such as hidden viral or bacterial infections, also diseases preceding RA may cause a failure immune response to viral or bacterial antigens [5].

Periodontal disease (PD) is a bacterial infection affecting the periodontium, which can cause increasing degradation of tooth-supporting soft- and hard tissues, ultimately resulting in tooth loss [6]. Gram-negative anaerobic bacteria, organized as a structured biofilm on the tooth surface are the primary cause involved in the initiation and the progression of PD [7]. The best described periodontal pathogens are Aggregatibacter actinomycetemcomitans, Tannerella forsythensis and Porphyromonas gingivalis (P. gingivalis) [8]. P. gingivalis, one of the major periodontal pathogens, is able to invade endothelial cells and human chondrocytes [9]. It is the only known bacterium expressing the peptidylargininedeaminase (PAD) enzyme, which is responsible for the post-translation and conversion of arginine to citrulline [5]. Citrulline modifications lead to the production of anti-CCP antibodies, which are found most frequently in RA patients [10]. Furthermore, aggressive periodontitis, affecting young individuals, is characterized by severe periodontal attachment loss and bone destruction. In comparison to adult periodontitis, aggressive periodontitis shows a more rapid disease onset and a faster progression. It was shown that a combination of mechanical and antibiotic treatment effectively provides favorable clinical results on periodontal and systemic health in generalized aggressive periodontitis patients [11]. In general, the selection of the antibiotic is adapted to the spectrum of bacteria (Table 2).

Increasing evidence shows that patients with RA have an increased prevalence of periodontal attachment loss compared to healthy
individuals [12]. Evidence from epidemiological studies suggests a bi-directional association [13]. In both the diseases, dysregulated immune responses seem the crucial factor facilitating tissue degradation and loss of function [14]. Intervention studies indicate causal relationship by showing that periodontal therapy has beneficial systemic effects on RA disease activity [15]. PD and PA are prevalent chronic inflammatory diseases associated with significant morbidity and mortality and therefore immense impact upon the economy, health and quality of life. RA and PD are associated with increased mortality due to a number of co-morbidities. Both are chronic inflammatory diseases associated with soft and hard tissue damage, a dysregulation of immune response and common genetic and lifestyle factors influencing the diseases [16].

A number of cross-sectional studies reported an increased incidence of PD in RA patients [17] and a higher prevalence for RA in patients suffering from PD. An increased risk for systemic diseases such as cardiovascular disorders, diabetes and osteoporosis was described for both diseases [18]. Therefore, next to the drug-therapy of RA and PD additional drugs may have to be administered for the treatment of the co-morbidities. Therefore, further undesired drug-drug interactions may be admitted by health professionals treating RA patients.

Drug metabolism is a complex biochemical network, which consists of many different parts and reactions in the human organism. Some drugs are excreted in urine and feces without passing any metabolic modifications in the liver. However, most of the systemic drugs have a multi-step metabolism (typically oxidation and conjugation). The oxidation reactions are mainly catalyzed by the Cytochrome P450 enzymes (CYPs) family of CYP enzymes [19], which belong to the family of monoxygenases has been the focus of pharmaceutical research for decades. CYPs catalyze a large amount of chemical reactions, such as alcohol oxidations, dehydrogenation and isomerizations. It is a difficult task of medical science and daily clinical practice to find effective and safe combinations of drugs that do not affect each other’s metabolic pathways. If this is not taken into account, severe adverse effects including death occur. The Human Genome Project discovered 57 human CYPs [20]. Due to many polymorphisms and inducability, the biological activities of the CYPs vary noticeable among humans, which is an important issue for researchers as well as clinicians. Knowledge of the level and the catalytic activity of the specific CYP as well as the effect on drug metabolism could and should lead to personalized drug dosages to optimize the therapeutic effect and minimize harmful side effects. If a drug induces a specific CYP, which is also active in another drug’s metabolism, the dosage of the first drug should be increased to achieve the same therapeutic effect [21]. In case of a CYP inhibition, the dosage can be reduced, which lowers side effects.

Due to multi-drug administration, adverse side effects, such as deadly acute renal failure (31) are discussed intensely in pharmaceutical research [22].

Frequently occurring problems, which we address here, are firstly adverse side effects because of enzyme overload and secondly, ineffective therapy because of enzyme induction or inhibition. Therefore, drug interactions in the therapy of RA and PD were analyzed in the present study.

Materials and Methods

Textmining

Information on drug metabolism is spread over 100,000 articles in PubMed. To collect relevant articles a specific search tool was developed. Abstracts of PubMed database were automatically filtered for relevant articles using specific keywords. Medical subject headings (MeSH) represent the National Library of Medicine’s vocabulary thesaurus and were used for disease definitions and synonyms. The abstracts were screened for WHO-drugs and their synonyms, as well as a set of human CYPs with synonyms and the papers found in PubMed were manually processed. Each drug was attributed to those CYPs that are involved in drug metabolism as a substrate, an inhibitor or an inducer.

Treatment schemes

Information on drug administration in the therapy of RA and PD was collected from scientific literature. Additionally, for RA, international recommendations [23] and for PD different national guidelines [24] could be taken into account. Web resources provided further information on drug metabolism, e.g. Nelsons Homepage [25], Flockharts Interaction table [26], University of Maryland’s Drug Checker, PubChem [27], Protein Data Bank [28] and FDA-files.

Drug classification

The recommendations of the WHO Expert Committee for updating the WHO Model List of Essential Medicines are updated annually [29]. In 2004, a list of all items, according to their 5-level Anatomical Therapeutic Chemical (ATC) classification code was published. The ATC-code classifies drugs into different groups according to anatomic site of action, therapeutic effect and chemical structure. The therapeutic subgroup, which is determined by the second level, was used to find drug alternatives.

Expression data

Affymetrics data were used to compare the CYP mRNA expression of human body tissues. The series of datasets taken from GEO (Gene expression Omnibus, http://www.ncbi.nlm.nih.gov/geo/) were generated from ten donors and represent normal human bodies (Series GSE3526, [30]). It contains seven different tissues, oral, pharyngeal, esophageal and intestinal mucosa, as well as skeletal tissue and bone. All probe sets related to Cytochromes were normalized and condensed to 40 types of CYPs. To assess differences in expression, a heat-map was built with Genesis [31].

Database and web-server

Two CYP interaction tables were generated for the therapy of RA and PD. Numerous problems, such as enzyme overload or enzyme induction and inhibition could occur in the combined therapy of RA and PD. Some of these drug-drug interactions are rather unnecessary because the choice of another antibiotic could already circumvent the problem. In the present study, a web-interface for clinicians to check drug-drug interactions was generated to overcome CYP based problems. The database provides information on drug metabolism including PubMed references. Based on the WHO classification system (ATC), the database provides drug alternatives.

The present database is designed as a relational database on a MySQL server. For chemical functionality, the MyChem package is included, which aims to provide a complete set of functions for handling chemical data within MySQL. The website is built with PHP and Javascript and the web access is enabled via Apache Webserver 2.2.

Results

The results of the present literature analysis are summarized in tables 1 and 2, respectively. Table 1 show that especially CYPs 2C8,
Expression

The built heat-map lists seven tissues involved in RA and PD and the expression of several CYPs therein (Figure 1). Expression ranges from -2.24-fold lower to 2.24-fold higher values. The CYP expression in target tissues has not been taken into account so far, but is an interesting issue because it is a major factor for the effective retention period. For example, CYP 3A7, which was formerly known as fetal enzyme, was recently shown to be upregulated in the bone [32]. This means that the function of the CYP 3A family is significantly increased, which leads to shorter duration of action of drugs like Paracetamol, Diclofenac, Prednisone, Fentanyl etc.

Discussion

In an aging society with increasing morbidities and co-morbidities drug interactions have to be realized and or prevented by health professionals. One of the most difficult tasks of the decision making process is to find combinations of drugs that do not affect each other’s metabolic pathways. Despite the large amount of information on CYPs, optimizing multiple drug prescriptions using CYP metabolism is still complicated [33]. Drug-drug interactions are complex and information on drug metabolism is spread over 100,000 articles in PubMed, which may be overwhelming and not possible to handle by the clinician. Information on CYP-structures [34], binding sites [35], interactions and different genotypes [36] must be combined to allow reducing side effects and to determine correct dosages of medicine undesired side effects when prescribing more than one drug [37]. To overcome this problem a tool for medical and dental clinicians was generated to identify and examine drug-drug interactions online. The SuperCYP database [38] contains information on 1,170 drugs with more than 3,800 interactions including scientific references. This comprehensive resource is freely available at http://bioinformatics.charite.de/perio and is also usable on smartphones and tablet-PCs and could be used as basis for personalized medicine.

Evidence of an association between RA and PD, two of the most common inflammatory diseases in humans, is increasing [39].

![Figure 1: Heat-map of target tissues in RA and PD and the expression of several CYPs therein. Expression ranges from -2.24-fold lower (green rectangles) to 2.24-fold higher values (red rectangles).](image-url)
In addition, both diseases are associated with systemic chronic inflammatory co-morbidities such as cardiovascular disease. Based on the fact that the medication of pain relieving and disease-modifying drugs can hardly be modified, it is primarily the dentist’s task to choose an antimicrobial agent for adjunctive periodontal treatment that is on the one hand most effective in its antibacterial efficacy and on the other hand does not negatively affect the therapy and its side effects in RA patients.

The present data on CYP metabolism suggests two key problems of drug-drug interactions in the treatment of PD in RA patients, discussed below (Tables 3 and 4). First, Aspirine, a commonly used NSAID in the therapy of RA, is metabolized by CYP 2C9 and 2C19 and induces 2C19, which is also the substrate of Amoxicilline, a β-lactam antibiotic drug often prescribed as antimicrobial therapy adjunctive to mechanical debridement in oral infections such as aggressive periodontitis. Due to induction of CYP 2C19 and inactivation of Amoxicilline may be possible. Therefore, a replacement by another group of antibiotic agent, such as Ciprofloxacine, which is also effective against periodontal pathogens, would be less harmful with respect to CYP metabolism, and therefore could easily bypass this problem (Table 3).

The table shows drug interactions of the NSAID, Aspirine, with antimicrobial drugs, Amoxicilline (red line because of the conflict regarding CYP 2C19 [orange cell]) and Ciprofloxacine. Ciprofloxacine avoids the CYP 2C19 conflict (green). "S" means substrate, "Ind" means inducer and "Inh" means inhibitor. Suggestions like that are automatically generated by the Web-Server using the classification and metabolic information stored on the server for the drug-cocktail entered by the user.

In addition, in the therapy of RA, NSAIDs and DMARDs are often combined with each other and drug-drug interactions often occur. If an antibiotic agent with the same metabolic pathway is administered, side effects because of enzyme overload are possible and could be avoided by choosing agents with different metabolic pathways. The NSAID, Oxaproxine, and the Leflunomide, a DMARD, share the same metabolic pathway via CYP 2C9. Additionally, Leflunomide inhibits CYP 2C8 and 2C9. Administration of Amoxicilline in combination with the antimicrobial drug, Metronidazol, which uses the same metabolic pathway as Oxaproxine and Leflunomide and inhibits the CYP, as well, could lead to adverse side effects because of enzyme overload. Clindamycine, which is also potent against periodontal pathogens, might be a good alternative (Table 4) [40,41].

Advances in genetic research have enabled genotyping and analysis of individual data on expression of target genes and metabolic enzymes. Such expression data in target tissues should be considered in selection of drugs.

### Table 3: Ineffective therapy because of enzyme induction or inhibition.

| Drug       | NSAID | 1A2 | 2C8 | 2C9 | 2C19 | 3A4 |
|------------|-------|-----|-----|-----|------|-----|
| Aspirine   | S     | S   | Ind |     |      |     |
| Amoxicilline| Antibiotic agent | S   |     |     |      |     |
| Ciprofloxacine | Antibiotic agent | Inh | Inh |     |      |     |

### Table 4: Potentially adverse side effects because of enzyme overload.

| Drug       | 2C8 | 2C9 | 2C19 | 3A4 |
|------------|-----|-----|------|-----|
| Oxaproxine | NSAID | S   |     |     |
| Leflunomide| DMARD | S, Inh | S, Inh | Inh |
| Metronidazol| Antibiotic agent | Inh | S, Inh | S, Inh |
| Amoxicilline| Antibiotic agent | Inh | S, Inh | S, Inh |
| Clindamycine| Antibiotic agent | Inh | S, Inh |     |

The Web-Server presented in this study provides a user-friendly platform enabling medical and dental health professionals to optimize drug choice and combinations regarding the degree of CYP capacity utilization. With respect to increasing evidence of associations between oral and systemic chronic inflammatory diseases, such as PD and RA, knowledge about drug interactions become crucial to optimize health care.

## Conflict of interest

There is no actual or potential conflict of interest.

**Acknowledgements**

The authors would like to thank Elena Kaschina for her critical reading of the manuscript.

**Authorship Contributions**

- Participated in research design: Preissner, Kuzman, Pischon
- Performed data analysis: Preissner, Kuzman
- Wrote manuscript: Preissner, Pischon

**References**

1. Lee DM, Weinblatt ME (2001) Rheumatoid arthritis. Lancet 358: 903-911.
2. Bykerk VP, Akhavan P, Hazlewood GS, Schleier O, Dooley A, et al. (2012) Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol 39: 1559-1582.
3. Schoels M, Knevel R, Aletaha D, Bijlsma JW, Breedveld FC, et al. (2010) Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 69: 638-643.
4. Ogerendik M (2009) Rheumatoid arthritis is linked to oral bacteria: etiological association. Mod Rheumatol 19:453-456.
5. Rosenstein ED, Greenwald RA, Kushner LJ, Weissmann G (2004) Hypothesis: the humoral immune response to oral bacteria provides a stimulus for the development of rheumatoid arthritis. Inflammation 28: 311-318.
6. Socransky SS, Haasfje AD (1992) The bacterial etiology of destructive periodontal disease: current concepts. J Periodontol 63:322-331.
7. Van der Velden U, Abbas F, Armnd S, Loos BG, Timmerman MF, et al. (2006) Java project on periodontal diseases. The natural development of periodontitis: risk factors, risk predictors and risk determinants. J Clin Periodontol 33: 540-548.
8. van Winkelhoff AJ, Loos BG, van der Reijden WA, van der Velden U (2002) Porphyromonas gingivalis, Bacteroides forsythus and other putative periodontal pathogens in subjects with and without periodontal destruction. J Clin Periodontol 29:1023-1028.
9. Pischon N, Röhrer E, Hocke A, N’Guessan P, Muller HC, et al. (2009) Effects of Porphyromonas gingivalis on cell cycle progression and apoptosis of primary human chondrocytes. Ann Rheum Dis 68: 1902-1907.
10. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Vrogen WJ (1998) Céluline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Invest 101: 273-281.
11. Tonetti MS (2009) Periodontitis and risk for atherosclerosis: an update on intervention trials. J Clin Periodontol 10: 15-19.
12. de Pablo P, Dietrich T, McAlindon TE (2007) Association of periodontal disease and tooth loss with rheumatoid arthritis in the US population. J Rheumatol 35: 70-76.
13. Mercado FB, Marshall RI, Bartold PM (2003) Inter-relationships between rheumatoid arthritis and periodontal disease. A review. J Clin Periodontol 30: 761-772.
14. Bartold PM, Marshall RI, Haynes DR (2005) Periodontitis and rheumatoid arthritis: a review. J Periodontol 76: 2066-2074.
15. Al-Katma MK, Bissada NF, Bordeaux JM, Sue J, Askari AD (2007) Control of
periodontal infection reduces the severity of active rheumatoid arthritis. J Clin Rheumatol 13: 134-137.

16. Detert J, Pischon N, Burmester GR, Buttgerelt F (2010) The association between rheumatoid arthritis and periodontal disease. Arthritis Res Ther 12: 218.

17. Pischon N, Pischon T, Kröger J, Gulmez E, Kleber BM, et al. (2008) Association among rheumatoid arthritis, oral hygiene, and periodontitis. J Periodontol 79: 979-986.

18. Antohe JL, Bili A, Sartorius JA, Kirchner H, Morris SJ, et al. (2011) Diabetes mellitus risk in rheumatoid arthritis: Reduced incidence with anti-tumor necrosis factor- alpha therapy. Arthritis Care Res (Hoboken) 64: 215-21.

19. Lepesheva GI, Hargrove TY, Kleshchenko Y, Nes WD, Villalta F, et al. (2008) CYP51: A major drug target in the cytochrome P450 superfamily. Lipids 43: 1117-1125.

20. Ingelman-Sundberg M (2005) The human genome project and novel aspects of cytochrome P450 research. Toxicol Appl Pharmacol 207: 52-56.

21. Gardiner SJ, Begg EJ (2006) Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 58: 521-590.

22. Angalakuditi M, Gomes J (2011) Retrospective drug utilization review: impact of pharmacist interventions on physician prescribing. Clinicoecon Outcomes Res 3:105-108.

23. Beikler T, Prior K, Ehmke B, and Flemmig TF (2004) Specific antibiotics in the treatment of periodontitis--a proposed strategy. J Periodontol 75: 169-175.

24. Nelson DR (2006) Cytochrome P450 nomenclature, 2004. Methods Mol Biol 320: 1-10.

25. Flockhart DA (2007) Drug Interactions: Cytochrome P450 Drug Interaction Table, Indiana University School of Medicine.

26. Geer LY, Marchler-Bauer A, Geer RC, Han L, He J, et al. (2010) The NCBI BioSystems database. Nucleic Acids Res 38: 492-496.

27. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic Acids Res 28: 235-242.

28. WHO Expert Committee (2009) The selection and use of essential medicines. World Health Organ Tech Rep Ser 1: 2-124.

29. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, et al. (2010) SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res 38: D237-D243.

30. Radhakrishnan ML, Tidor B (2008) Optimal drug cocktail design: methods for targeting molecular ensembles and insights from theoretical model systems. J Chem Inf Model 48: 1055-1073.

31. Page RC, Offenbacher S, Schroeder HE, Seymour GJ, Komman KS (1997) Advances in the pathogenesis of periodontitis: summary of developments, clinical implications and future directions. Periodontol 2000 14: 216-248.